Taking large pills can be problematic for patients with swallowing difficulties, the elderly and children. One way to overcome this challenge is the use of sublingual or buccal application forms. Due to the high number of capillaries in the mouth floor and the relatively permeable mucosa, the drug can be taken-up rapidly by the body. This allows the drug to enter the blood flow without the influence of the intestine, gastric acid and first pass effect. Additionally, this can lead to a shorter onset time to reach the minimal effective concentration with lower drug doses compared to oral administration. Another challenge is the poor water solubility of new drugs and drug candidates. One method to increase the apparent water solubility of the drug is the preparation of the amorphous form of the drug, as this can improve the dissolution rate and oral bioavailability. However, the physical instability and recrystallization tendency of the amorphous form is a major issue. To overcome this, amorphous solid dispersions (ASDs) can be prepared, wherein the amorphous form of a drug is stabilized using suitable excipients, e. g., through tuning the interactions between polymeric excipients and drugs. This is not only stabilizing the amorphous form, but also influencing the dissolution profile and therefore the bioavailability of the drug. Common polymer excipients for the preparation of ASDs are poly(vinyl pyrrolidone) , poly(vinyl pyrrolidone-co-vinyl acetate) or hydroxypropyl methylcellulose . Previously, poly(2-oxazoline) (POx) and poly(2-oxazine) (POzi) bearing polymers were explored as excipients. Especially, amphiphilic ABA triblock copolymers comprising POx/POzi have been used for the formulation of drugs with low water solubility with drug loading up to 50wt%. More recently, these polymers were studied regarding the stabilization of drug nanocrystals and in drug loaded microneedles .